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iSUMMARY
Estrogens function as the primary female sex hormones in women of reproductive age.
It promotes the development of female secondary sexual characteristics, and is an
essential part of a woman’s reproductive process. Recent studies indicate that about
80% of breast cancers, once established, are estrogen dependent. These are known as
hormone-sensitive or hormone-receptor-positive cancers. ERα is the key transcription
regulator of this breast cancer progression. It is over-expressed in around 70% of
breast cancer cases and estrogen has been shown to stimulate proliferation of
mammary cells.
Using high-throughput ChIP (Chromatin ImmunoPrecipitation)-based technology,
such as ChIP-Seq (ChIP process followed by sequencing), we generated a global map
of ERα binding sites in the genome of MCF7 breast cancer cell line. From this dataset,
we identified two ERα binding sites near the RET (rearrangement during transfection)
gene. RET is a proto-oncogene that encodes a receptor tyrosine kinase. It has been
shown to be involved in human papillary thyroid tumors and in multiple endocrine
neoplasia type 2. Previous studies have shown the RET gene is expressed in primary
breast tumors and cell lines. In MCF7 cells, the expression of RET, the activation of
its downstream signaling pathways, and the increase of anchor-independent
proliferation have been shown to be estrogen dependent. In addition, RET expression
is up-regulated by estrogen treatment and knock down of ERα down-regulates RET.
ii
We verified that two ERα binding sites within the RET locus, which are located 50kb
upstream and 35kb downstream of the transcription start site, are recruited upon
estrogen stimuli. Using Chromosome Conformation Capture assay, we showed that
these two ERα binding sites are brought in close proximity with each other and with
the promoter region of the RET gene in an estrogen dependent manner. Knock down
of ERα disrupted this long-range interaction. In addition, we showed that
co-regulatory factors, such as FoxA1, cJun, and AP2γ are recruited to these two ERα
binding sites. Among them, AP2γ knock-down resulted in a decrease of RET
expression and a concomitant decrease in long range chromatin interaction. Taken
together, these results suggest that ERα collaborates with other DNA binding
transcription factors to form chromatin loops which directly regulate the transcription
of the RET gene in breast cancer cells.
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1Chapter 1 Background
1.1 Breast Cancer and Estrogen
1.1.1 Breast cancer and estrogen
Breast cancer is the second ranking cancer worldwide and it is the fifth most common
cause of cancer death (Breast Cancer Facts & Figures 2009-2010, American Cancer
Society, Atlanta, Georgia). With decades of molecular pathology research and clinical
trials, breast cancer is also one of the most well studied cancer types now and its
survival rate after therapy is increasing (Wooster and Weber 2003). Established breast
cancer cell lines, such as MCF7, is now a common model for the study of breast
cancer.
Based on the dependency of hormones, breast cancers can be generally divided into
two groups, hormone-sensitive and hormone-insensitive breast cancers. The first
group, which constitutes about 80% of all breast cancers, is also known as
hormone-receptor-positive breast cancers. Such cancers, once established, rely on the
hormone estrogen to grow (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001; van de
Vijver, He et al. 2002; Yager and Davidson 2006; Sadler, Pugazhendhi et al. 2009).
21.1.2 Estrogen and its role in human physiology
Estrogens (or oestrogens) are a group of steroid compounds, named for their
importance in the estrous cycle (Nelson and Bulun 2001; DeNardo, Kim et al. 2005).
Estrogen functions as the primary female sex hormone. There are three major
naturally occurring estrogens in women: estrone (E1), estradiol (E2), and estriol (E3)
(Dahlman-Wright, Cavailles et al. 2006). Even though estrogens are present in both
men and women, they are usually present at significantly higher levels in women of
reproductive age. They promote the development of female secondary sexual
characteristics, such as breasts, and are also involved in the thickening of the
endometrium and in the regulation of the menstrual cycle (Yager and Davidson 2006).
In males, estrogen regulates specific functions of the reproductive system that are
important in the maturation of sperm and may be necessary for a healthy libido (Hess,
Bunick et al. 1997).
1.1.3 Estrogen and the estrogen receptor
Estrogen functions through binding to the estrogen receptors. The estrogen receptor
(ER) belongs to a subfamily of the nuclear receptor superfamily (Nilsson, Makela et
al. 2001). There are two isoforms of the ER, ERα and ERβ, and each is encoded by a
separate gene, ESR1 and ESR2, respectively (Leung, Mak et al. 2006). Despite this,
ERα and ERβ show significant overall sequence homology (Ascenzi, Bocedi et al.
32006).
Like other members of the nuclear receptor superfamily, the ERs have three major
domains, the Activation Function domain, the DNA Binding Domain and the Ligand
Binding Domain (Shiau, Barstad et al. 1998). After estrogen activation, the estrogen
receptors may form 3 different dimers, ERα or ERβ homodimers or ERαβ
heterodimers (Couse, Lindzey et al. 1997; Li, Huang et al. 2004). Across various cell
types, the ERα homodimer is the most common one and is over-expressed in 70% of
breast cancer cases (Deroo and Korach 2006). Estrogen activates ERα and stimulate
the proliferation of mammary cells (Fabian and Kimler 2005). Indeed, ERα has been
shown to regulate important cell cycle genes, such as Cyclin D1 and DNA
methylation genes, such as O-6-methylguanine-DNA methyltransferase (Metivier,
Penot et al. 2003; Bjornstrom and Sjoberg 2005; Levin 2005).
1.1.4 Molecular mechanism of the estrogen receptor
In the classical model, ERs are activated through ligand binding. Binding of estrogen
to the receptors leads to homodimerization. The homodimers subsequently bind to
specific response elements known as estrogen response elements (EREs) located in
the promoters of the target genes to assist transcription (Nilsson, Makela et al. 2001).
Estrogen binding also induces conformational changes within the ligand binding
domain of the ERs, and this change allows coactivator proteins to be recruited
4(Rosenfeld and Glass 2001). In total, one third of the genes in humans that are
regulated by ERs can be activated in this ERE-dependent manner (O'Lone, Frith et al.
2004).
Besides this classical model, ERs can regulate gene expression without binding
directly to DNA by modulating the function of other transcription factors through
protein-protein interactions (Gottlicher, Heck et al. 1998). Several genes are activated
by E2 through the interaction of ERs with cJun and cFos proteins at AP-1 binding
sites within the promoter of genes such as IGF-I (Umayahara, Kawamori et al. 1994)
and cyclin D1 (Sabbah, Courilleau et al. 1999; Liu, Albanese et al. 2002). Besides
AP-1 binding sites, ERs also regulate GC-rich promoter regions with the Sp1
transcription factor (Porter, Saville et al. 1997; Li, Briggs et al. 2001). These
ERE-independent actions mainly rely on the tethering of ERs to other DNA binding
transcription factors so as to enhance ER transcriptional regulation (Bjornstrom and
Sjoberg 2005).
1.2 RET Gene
1.2.1 RET and its isoforms
RET proto-oncogene was named because of its Rearrangement during Transfection
(Takahashi, Ritz et al. 1985). The DNA sequence of this gene was originally found
5to be rearranged within 3T3 fibroblast cell line following its transfection with DNA
taken from human lymphoma cells. In human, RET gene is located in chromosome 10
(10q11.2) and contains 21 exons (Takahashi 1988; Takahashi, Buma et al. 1988;
Ishizaka, Itoh et al. 1989).
The RET gene encodes a receptor tyrosine kinase (RTK) which belongs to the glial
cell line-derived neurotrophic factor (GDNF) family of extracellular signaling
molecules (Durbec, Marcos-Gutierrez et al. 1996; Trupp, Arenas et al. 1996; Baloh,
Tansey et al. 1998). Alternative splicing results in 3 different isoforms of RET, RET9,
RET43 and RET51, based on the 9, 43 and 51 amino acids in their C-terminal tail
respectively (Tahira, Ishizaka et al. 1990; Myers, Eng et al. 1995; de Graaff, Srinivas
et al. 2001). RET43 is seldom found in human (Myers, Eng et al. 1995).
The RET protein is divided into 3 domains. In the N-terminal extracellular domain
there are four cadherin-like repeats and a cysteine-rich region. The hydrophobic
transmembrane domain and the cytoplasmic tyrosine kinase domain are separated by
an insertion of 27 amino acids. Within their cytoplasmic domains, there are 16
tyrosines (Tyr) in RET9 and 18 tyrosines in RET51 (Hayashi, Iwashita et al. 2001;
Kurokawa, Iwashita et al. 2001). Tyr1090 and Tyr1096 are unique for RET51 (Knauf,
Kuroda et al. 2003; Kawamoto, Takeda et al. 2004).
61.2.2 RET gene and its role in human physiology
Mice deficient in GDNF, GFRα1 or the RET protein exhibit severe defects in kidney
and enteric nervous system development (Trupp, Scott et al. 1999; Lee, Chan et al.
2002). This implicates that RET signal transduction is a key pathway in the
development of normal kidneys and the enteric nervous system. RET loss of function
mutations are associated with the development of Hirschsprung's disease, while gain
of function mutations are associated with the development of various types of human
cancer, including medullar thyroid carcinoma, multiple endocrine neoplasias type 2A
and 2B, phaeochromocytoma and parathyroid tumors (Ishizaka, Itoh et al. 1989;
Donis-Keller, Dou et al. 1993; Mulligan, Kwok et al. 1993; Edery, Lyonnet et al. 1994;
Hofstra, Landsvater et al. 1994; Romeo, Ronchetto et al. 1994; Eng 1999).
Recently researchers have also demonstrated the role of RET in tumors progression
from non-neuroendocrine origin. Furthermore, detection of RET mutations in
pancreatic cancer and the over expression of genes in the RET RTK pathway in breast
tumor cell lines suggest that RET have important roles in the regulation of cancer
growth and progression (Hayashi, Ichihara et al. 2000; Dechant 2002; Tsui-Pierchala,
Milbrandt et al. 2002; Sawai, Okada et al. 2005; Zeng, Cheng et al. 2008).
71.3 Long Range Chromatin Interactions
1.3.1 Estrogen receptor binding sites in breast cancer
The human genome is comprised of 23 pairs of chromosome with a total of 3 billion
base pairs (Lander, Linton et al. 2001; Venter, Adams et al. 2001). However, only
1.5% of the genome encodes for about 23,000 of all protein-coding genes. Within the
non-coding sequences, there are many different kinds of regulatory elements which
provide crucial control of gene expression. These elements include insulators,
boundary elements and transcription factor binding sites (Maston, Evans et al. 2006).
One of the important functions of these regulatory elements is their role as
recruitment sites for protein factor to carry out their regulatory functions (West and
Fraser 2005). Chromatin Immunoprecipitation (ChIP) is widely used to detect such
protein-DNA interactions and ChIP-Seq provides us with the tools to map the position
of these regulatory sites across the genome (Kuo and Allis 1999). For example,
traditional ChIP assay using a specific antibody against ER isolates chromatin
fragments bound by the receptor. By performing traditional or quantitative PCR with
specific primers, estrogen receptors binding at specific locations in the genome can be
easily detected. By coupling ChIP with massive sequencing technology, the whole
pool of estrogen binding fragments can be sequenced and mapped back to the human
genome revealing the exact positions of estrogen receptor binding site (ERBS). In
8addition, ChIP-Seq also contains information on the density or strength of receptor
binding.
Based on such technology, numerous binding maps of important transcription factors
have been generated, including p53, Oct4 and Nanog (Loh, Wu et al. 2006; Wei, Wu
et al. 2006). For the estrogen receptor, at least five genome-wide maps of ERα
binding in MCF7 cells have been generated beside numerous other partial maps based
on chromosomes, promoters or custom loci (Cheung and Kraus, 2009). Based on the
different technique, 8,525 ERα binding sites were detected by ChIP-chip (Hurtado,
Holmes et al. 2008), 10,205 sites by ChIP-Seq (Welboren, van Driel et al. 2009) and
1,234 sites by ChIP-PET in estradiol-stimulated MCF7 cells (Lin, Vega et al. 2007).
Surprisingly, only a small portion of these binding sites were found in the proximal
promoter region of genes while the majority were distributed across the genome,
mostly in the region around 5-100 kb from the 5’- and 3’- ends of the adjacent
transcripts. Such binding characteristics were also observed in other transcription
factor and in other cell lines. This suggests that such transcription factors may
regulate transcription through long-range chromatin interactions.
1.3.2 Methods to study long range chromatin interactions
Chromosome Conformation Capture (3C) is the most widely used method to study
long range chromatin interactions across the genome (Dekker, Rippe et al. 2002). The
9main concept behind the 3C technique is based on the “proximity ligation” concept of
the Nuclear Ligation Assay (Cullen, Kladde et al. 1993). In the 3C assay, the
chromatin is cross-linked with formaldehyde in the same way as in the ChIP assay
and digested by a restriction enzyme. The sticky ends of the fragments are ligated to
each other according to their spatial distances. Hence, fragments in close proximity
are more likely to ligate at a higher frequency. A classic example of this long-range
chromatin interaction is between the ß-globin locus and locus control regions in
mammalian cells (Tolhuis, Palstra et al. 2002).
Although 3C is a powerful technique, it does have several limitations (Fullwood and
Ruan 2009). First and most important of all, 3C experiments have high noise levels.
Consequently, 3C analysis relies on a set of control experiments to distinguish real
signals from noise, which makes 3C assay laborious and tedious (Dekker, Rippe et al.
2002). In addition, 3C methods are limited to single point interactions of previously
known or hypothesized interaction sites. In order to overcome these disadvantages,
several groups have developed new techniques based on the principles of 3C (Simonis,
Kooren et al. 2007), these include 3D (Hu, Kwon et al. 2008), Associated Chromatin
Trap (ACT) (Ling, Li et al. 2006), Chromosome Conformation Capture using Chip
(4C) (Simonis, Klous et al. 2006), Circular Chromosome Conformation Capture (also
called 4C) (Zhao, Tavoosidana et al. 2006), Open-ended Chromosome Conformation
Capture (Wurtele and Chartrand 2006) and Chromosome Conformation Capture
Carbon Copy (5C) (Dostie, Richmond et al. 2006). Notably, 3D improves the
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sensitivity of detection with DNA capture by using a specific biotinylated
oligonucleotide followed by DNA selection and ligation. This additional step detects
co-captured DNA fragments in a high-throughput and unbiased fashion, which in turn,
enhances the ability to detect long range chromatin interactions (Hu, Kwon et al.
2008). These new techniques provide new capabilities to detect long range chromatin
interactions, but are still constrained by their ability to provide a genome-wide view.
The development of highly efficient, low noise, genome-wide, and de novo method to
detect the long range interactions remains a challenge (Fullwood and Ruan 2009).
Recently a new strategy, chromatin interaction analysis by paired-end tag sequencing
(ChIA-PET), was designed to detect the global chromatin interactions (Fullwood, Liu
et al. 2009). In ChIA-PET, the long-range chromatin interactions are captured by
cross-linking with formaldehyde. The sonicated DNA-protein fragments are enriched
by ChIP process, followed by adding linkers and proximity ligation. The paired-end
tags are extracted, purified and sequenced. The sequencing results are mapped to the
reference genome to reveal the chromosome regions that are brought into close spatial
proximity through chromatin looping. This unbiased whole-genome approach has
greatly advanced our ability to study higher order organization of chromosomal
structures and functions (Fullwood, Liu et al. 2009).
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1.3.3 Long range chromatin interactions of the estrogen receptor
Long range chromatin interactions mediated by the estrogen receptor of selected
genes has been reported by others. Using mainly 3C or 3C followed by ChIP, long
range chromatin interaction of distal ERα binding region and the proximal promoter
region has been reported for key E2 regulated genes such as TFF1 (Carroll, Liu et al.
2005; Pan, Wansa et al. 2008) and GREB1 (Deschenes, Bourdeau et al. 2007). Long
range chromatin interaction of the ERα binding site (144 kb upstream) with the
promoter of the NRIP-1 gene (Carroll, Liu et al. 2005), a ~ 6 kb upstream ERα
enhancer and the promoter of the CA12 gene (Barnett, Sheng et al. 2008) and a ~9 kb
upstream enhancer and the promoter of CTSD gene (Bretschneider, Sara et al. 2008)
were also reported to be mediated by ERα. Another recent example on ERα mediated
chromatin loop formed between the ERα binding site within the ERBB2 intron and
the ERBB2 promoter (Hurtado, Holmes et al. 2008), suggested that binding sites
within introns also contribute to long range chromatin interaction.
With the recently developed 3D assay, the first interchromosomal interaction between
the distal ERα binding sites of TFF1 (on chromosome 2) and the proximal ERα
binding sites of GREB1 (on chromosome 21) were detected (Hu, Kwon et al. 2008).
Due to the dependence on ligand activated ERα, these recent data indicates a key role
of ERα in the mediation of long range chromatin interactions.
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Using the ChIA-PET assay, a genome-wide chromatin interaction network mediated
by ERα was comprehensively mapped in MCF7 cells (Fullwood, Liu et al. 2009). In
all by 1,451 ERα mediated intrachromosomal and 15 ERα mediated
interchromosomal long range interactions were reported. These interactions were
mostly anchored from distal ERα binding sites to gene promoters and suggest that
transcription regulation by distal ERα binding sites primarily function through long
range chromatin interaction. Data from the ERα ChIA-PET study has provided a
valuable starting point for future studies on the function of these distal enhancers and
the relevant genes that they target.
1.4 Aims and objectives of the study
Comparing the microassay results of the E2 regulation genes with the ChIP-Seq
database, we detect a serial of ERBSs around the possible E2 regulated genes. From
the ChIA-PET data, we are able to build a possible link between the distal ERBSs
with the target genes. This study narrows down to a specific E2 regulated gene, RET,
to investigate the estrogen regulation pattern and the corresponding ERα binding
affinity. More importantly, this study aims to investigate the possible long range
chromatin interactions around this target gene, which could be another solid example
to accomplish the ERα conducted chromatin interaction network. Besides, we also
intend to investigate whether the co-factors of ERα, like cJun, FoxA1, etc, have
functions in the ERα conducted chromatin looping.
13
Chapter 2 Material and Methods
2.1 Plasmids construction
2.1.1 PCR amplification
Polymerase chain reaction (PCR) is a technique to amplify a single or few copies of a
piece of DNA across several orders of magnitude, generating millions or more copies
of a particular DNA sequence. Standard PCR was performed in a 25 µl reaction using
PTC-100TM peltier thermal cycler (Biorad, USA), Geneamp PCR system 9700
(Applied Biosystems, USA). A PCR reaction included 2.5 μl 10×PCR buffer, 1.5 μl
25 mM MgCl2, 0.5μl of 10 mM dNTP mix, 1 μl cDNA (from first-strand reaction),
1μl amplification primer 1, 1 μl amplification primer 2, 0.2 μl Taq DNA polymerase
(5 unit/μl), and 17.3 μl autoclaved, distilled water. The parameters for standard PCR
consists of first denaturation at 94°C for 3 minutes, followed by 35 cycles of
amplification process including denaturation at 94°C for 30 seconds, annealing at
55°C for 30 seconds and extension at 72°C for 1 minute and a final extension at 72°C
for 10 minutes. PCR primers used to amplify the ERBSs are indicated in Table 1.
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Forward Reverse
ERBS 1 ATCCACACATCCCTTCTGCT GGAAAGGGAGAGGAGCGAGAT
ERBS 2 CCCCAACTAATTCCCTTGGT GTCAGAGTGTGGATGCTTGGA
ERBS 3 GCAGAGCAGTGAGGCACAG GGAGGGAGCCCTCATCTGAA
ERBS 4 CTAGGAGGGAAGGGGAGTTG GAATGTCTGCCAGGAGAATGC
ERBS 5 GGATTGGCGCTGAGACAATG CTGTAGGGCCACAGGTTCTC
ERBS 6 CTCGCCATCTGTGGAACTTT GCCTGTAATGGCCTGAGGGTA
Table 1: Primer sets used to amplify the 6 ERBSs.
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2.1.2 Homologous recombination
The In-Fusion 2.0 PCR Cloning Kits (Clontech, USA) are designed to join multiple
pieces of DNA which have 15 base pairs of homology at their linear ends. During the
PCR process, the PCR primers have at least 15 bases of homology with sequences
flanking the desired site of insertion in the cloning vector. In general, 100 ng of the
linearized vector with 2 times of PCR fragment were added into one reaction of the
kit and the final volume was adjusted to 10 μl using deionized H2O. The reactions
were incubated for 15 min at 37℃ followed by 15 min at 50℃ and then transferred to
ice. Then the reaction mixture were diluted with 40 μl TE buffer (pH=8) and mixed
well. The products can be directly used for transformation or stored at -20℃.
2.2 Mutagenesis
The QuickChange Lightning Multi Site-Directed Mutagenesis Kit (Stratagene) can be
used to introduce multiple site mutations into the sequences we want. Primers may be
designed to bind to adjacent sequences or to well-separated regions on the same
strand of the template plasmid, with the desiring changes to introduce the mutations.
Primers are between 25 and 45 bases in length, with a melting temperature (Tm)
greater than 75°C. The estimated Tm is calculated based on the following formula:
The desired point mutation or degenerate codon is designed close to the middle of the
16
primer with ~10–15 bases of template/complementary sequence on both sides.
Optimum primers have a minimum GC content of 40% and terminate in one or more
C or G bases at the 3’-end. The primers used in mutagenesis process are listed here in
Table 2. The following procedures were carried out according to the manufacture’s
recommendation.
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ERE in ERBS 1 CAAGGTGCGCGGAGCCCAGAGGGTGATTCAGCTTGCTGACGAG
ERE in ERBS 6 GAACCTCGAGGCCCTGAATTGCCTTGATATCCAGCTCCCAGGAAC
AP2γ in ERBS 1 TCCGGGACAACGCGAACAGGGGCTCTGGAC
AP1 in ERBS 1 GCAGGTGAGACTGGCAAAGTTTGACCTGCTGCCGG
AP4 in ERBS 1 CTGAGTCAGACAAGCAACCGGGGCAGACGCAGGACAAGG
FoxA1 in ERBS 1 TCACCACGGTAATGCTGTATTGGGGCCTGGCACCATCACC
AP1 in ERBS 6 GCGGCTTTGTTGTCAAAGTTTGGGAGGAAAGGGGAGTAAAGG
AP2γ in ERBS 6 GTTGAGTCAGGGCCTGAATGGAACTTTTCCTGCCACC
AP4 in ERBS 6 GCTCCCAGGAACAGGGGTTGCAAGTAACATGTGG
FoxA1 in ERBS 6 GAAAGGGGAGTAAACCGTTGAAACAGGGCCTGCCTGGG
Table 2: Primers used to introduce mutations into transcription factor binding motif.
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2.3 Cell Culture, Transfection and Luciferase Assays
2.3.1 Cell culture
Early passage MCF7 cells (ATCC, Virginia) were cultured in DMEM, containing 5%
Fetal Bovine Serum (Gibco, Invitrogen, California) with 50000U of
penicillin/streptomycin (Gibco, Invitrogen, California) and 15 mg of gentamycin
(Gibco, Invitrogen, California), at 37°C and 5% CO2. The cells were PBS washed
twice, trypsinised by 1 ml trypsin (Gibco, Invitrogen, California) and incubated at
37°C for approximately 3 min. the cells were then washed from the surface of the
flask with 3 ml of the passage medium and then pipette up and down repeatedly to
obtain single cell suspension. The MCF7 cells were then subcultured at 1:2 ratio
where 2 ml of cells were added to 8ml of MCF7 passage medium to new flasks.
Before the estrogen stimulation, the MCF7 cells were transferred into serum starve
medium (containing 5% CD-FBS with penicillin, streptomycin and gentamycin in
phenol red-free DMEM/F-12 medium) for at least 72 hours.
2.3.2 Transient transfection and luciferase/renilla dual reporter assay
MCF7 cells were seeded into 24 wells plates at around 70% confluence in starving
medium for 3 days. Then 250 ng of the plasmid constructs, with 5 ng of the renilla
plasmids were incubated with 0.75 µl Lipofectamine 2000 (Invitrogen) for 20 min
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before adding into the corresponding wells. Each plasmid constructs were transfected
in 6 individual wells. 8 hours later, estrogen (E2) or ethanol (EtOH) were added to a
final concentration of 100 nM for 3 of the 6 wells. Cells were harvested 24 hour post
drug treatment. Then the samples were processed to the luciferase/renilla dual reporter
assay (Promega) using TriStar LB 941 machine (Berthold Technologies).
2.4 Chromatin immunoprecipitation assay
Following the indicated time of drug treatment (usually 45 min of 100 nM estrogen or
vehicle), MCF7 cells were cross-linked with 1% formaldehyde (Sigma-Aldrich,
Missouri) at room temperature for 10 min, then stopped with 125 mM glycine for 5
min, with slow rotation. Cells were washed by PBS twice, collected, and resuspended
in lysis buffer with 1× protease inhibitor cocktail (Roche), and sonicated for 8-10 min
in a Biorupter (Diagenode) to generate DNA fragments with an average of 500 bp.
The supernatant was diluted 5-fold by dilution buffer, pre-cleared with Protein-A
Sepharose beads, and immunoprecipitated with specific antibody. Precipitates were
washed with 1 ml of washing buffer, then the chromatin complexes were incubated at
room temperature with elution buffer. After de-crosslinking by incubating at 65℃
overnight, the ChIP DNA was purified using QIAquick columns (QIAGEN,
California) and then forward to quantitative real time PCR analyses with SYBR green
master mix kit (Applied Biosystems, California) on the ABI PRISM 7900 Sequence
Detection System(Applied Biosystems, California). For each reaction, 5 µl of the 2 ×
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SYBR green master mixes was used with 2 µl of the ChIP material and 3 µl of the
corresponding primer sets to make a 10 µl real-time PCR system. Primers were
designed to detect specific genomic loci using Primer Express 3 or Primer 3 online
(http://frodo.wi.mit.edu/primer3/). The primers used to detect the ERBSs from ChIP
samples are listed in Table 3.
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Forward Primer Reverse Primer
ERBS 1 CCCTGAGGGCGCAGAGA GGGATGGCAAGGTTAGAAGCT
ERBS 2 GGAACAGACACCAGCATATCCA CCTCGGTTTCCCTTTCTTTGA
ERBS 3 GGCATAAGCTCTGTGCAAACAT CATTTCCATGGTGTTTTATTAAAGGA
ERBS 4 TGTTCTCTCCCTGCGAGTTGT GAAGGAGCGACGCAACCA
ERBS 5 AAGGAGTGGCTCCACAAAGTGT TGCAGCGGTGACCTTTCTG
ERBS 6 CCCCCCTAGATCGGGAAAG ACGTTGATGCCACTGAATGC
Table 3: Primer sets used to detect the 6 ERBSs.
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2.5 Capture of Chromosome Conformation
2.5.1 3C assay
MCF7 cells were grown in the same way as preparing for ChIP assays above and
treated with the 100 nM indicated ligand or vehicle for 45 min prior to fixation in 1%
formaldehyde (Sigma-Aldrich, Missouri) for 10 min. Following that 125 mM glycine
was added to stop the cross-linking. Cells were washed by PBS twice and then harvest
into 15 ml falcon tubes. Cells were lysed in 5 ml cold lysis buffer (0.25% Triton
X-100, 10 mM EDTA, 10 mM Tris­HCl, pH=8.1, 100 mM NaCl and 1× protease
inhibitors) at 4℃ for 20 min with slow rotation. Released nuclei were collected by
centrifuge at 3,000g for 10 min then re-suspended in 1× enzyme buffer with 0.3%
SDS and 1.8% Triton-X. Chromatin was digested by BtgI (New England Biolabs)or
XhoII (Fermentas) overnight at 37℃ while rotating. Samples were heated to 65℃ to
deactivate the enzyme and then ligation buffer and T4 ligase (New England Biolabs)
were added into the samples. Samples were incubated in 16℃ for at least 4 hours,
then at room temperature for 1 hour, followed by 65℃ de-crosslinking overnight. 7
ml of phenol-chloroform was added into the tube and mixed vigorously by vortexing
for 30 sec. The samples were centrifuged at 2,200g for 15 min at 4 ℃ . The
supernatants were transferred into a new 50 ml tube and 7 ml of distilled water, 1.5 ml
of 2M sodium acetate (pH=5.6) with 35 ml of ethanol were added. After mixing the
tubes were placed at -80 ℃ for approximately 1 hour. Then the mixture were
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centrifuge at 2,200g at 4℃ for 45 min. The DNA samples were collected at the
bottom of the tube. Samples were washed by 10 ml of 70% ethanol then dissolved in
200 µl TE buffer (10mM Tris-Cl, 1 mM EDTA, pH=7.5).
2.5.2 Primer design and qPCR
The ligated DNA samples were purified again using QIAquick columns (QIAGEN)
before processing to the PCR amplification. For each reaction, 5 µl of the 2× SYBR
green master mix (Applied Biosystems, California) was used with 3 µl of the ligated
DNA material and 2 µl of the corresponding primer sets to make a 10 µl real-time
PCR system. Quantitative real time PCR analyses were carried out on the ABI PRISM
7900 Sequence Detection System (Applied Biosystems, California). The primers were
designed based on the targeting genomic region and the corresponding restriction
enzyme digestion sites. The suitable primers were positioned around 50-80 bps
upstream the digestion sites, which made the PCR product at around 100-150 bps.
























Table 4: Primer sets used for the 3C assay.
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2.5.3 BAC control
The control of the 3C PCR process was generated in BAC (Bacterial Artificial
Chromosome) covering the same region as RET position. Single colony of BAC
cloning RP11-669H9 (Invitrogen) was amplified in 50 ml LB medium with
chloramphenicol at 37 ℃ overnight. Then the BAC DNA was purified using
NucleoBond® BAC 100 kit (Macherey-Nagel). The bacteria was harvested from LB
culture by centrifugation at 4,500g for 15 min at 4℃. Then the pellet of bacterial cells
was resuspended in 24 ml Buffer S1 with RNase A. Then 24 ml of Buffer S2 was
added to the suspension. The mixture was inverted several times and was incubated
for 5 min. Following that, 24 ml of pre-cooled Buffer S3 (4℃ ) was added to the
suspension and the lysate was mixed several times to get a homogeneous suspension.
Then the suspension was centrifuged at 12,000g for 40 min at 4 ℃ . Then the
supernatant was filtered by a NucleoBond® Fold Filter. The cleared lysate was loaded
onto the NucleoBond® column to allow the DNA to bind. Following that the column
was washed twice by 18 ml Buffer N3, then eluted with 15 ml Buffer N5. 11 ml of
room-temperature isopropanol was added into the solutions and processed to
centrifuge at 15,000g for 30 min at 4℃. After discarding the supernatant, 5 ml of the
70% ethanol was added to wash the pellet. The samples were centrifuged again at
15,000g for 10 min then carefully discard the ethanol. The DNA pellet was
reconstituted in 200 µl buffer TE (10 mM Tris-Cl, 1 mM EDTA, pH=7.5).
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1 µg of the BAC DNA was processed for digestion and ligation. 1 µg of the BAC
DNA was mixed with 4 µl of the 10× restriction enzyme buffer and 2 µl of the
appropriate restriction enzyme in a 40 µl digestion system. The mixture was incubated
at 37℃ overnight. Then 5 µl of the 10× ligation buffer and 5 µl of the ligase was
added into the tube to ligate the fragments. The tube was incubated at 16℃ for 4
hours then left at room temperature for 1 hour. The ligation products were purified
using QIAquick columns (QIAGEN) then precede to real-time PCR.
2.6 RNA expression
RNA was purified using Invitrogen’s RNA purification kit and converted to cDNA
using MMLV Reverse Transcriptase (Promega). Quantitative real-time PCR analyses
was carried out using SYBR green master mix kit (Applied Biosystems, California)
on the ABI PRISM 7900 Sequence Detection System(Applied Biosystems,
California). For each reaction, 5 µl of the 2× SYBR green master mix was used with
3 µl of the cDNA material and 2 µl of the corresponding primer sets to make a 10 µl
real-time PCR system. The cDNA primers were designed using primer express 3 to
cover at least one junction of the exons. The target gene expression level was













Table 5: Primer sets used to detect mRNA expression level.
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2.7 Protein expression
2.7.1 Total protein extraction
MCF7 cells in 6 wells plate were washed by PBS twice, then 100-200 µl of cold lysis
buffer were added with shacking for 20 min. Cell lysate were transferred into a new
tube and centrifuged at 13,200 g for 15 min. The supernatant was carefully removed
into a new tube and stored at -80℃ or directly taken to use. The concentration of the
protein samples were measured by protein assay following the manufacturer’s
instructions (Pierce).
2.7.2 SDS-polyacrylamide gel electrophoresis
SDS-PAGE is a commonly used method for separation of proteins based on weight
and electrical properties as they migrate through a polyacrylamide matrix. 40 ng of
the samples were mixed with 2× SDS-gel loading buffer (50 mM Tris-HCl pH=6.8,
4% SDS, 0.02% bromophenol blue, 20% glycerol, 100 mM DTT) and heated to 95℃
for 5 minutes before loading into the wells. Electrophoresis was carried out by
Bio-Rad
Mini-PROTEAN in 5× Tris-glycine electrophoresis buffer at 10 mA for 10 min, then
at 20mA until the blue dye run out of the gel.
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2.7.3 Western Blotting
After SDS-PAGE electrophoresis, the protein samples were transferred to
nitrocellulose membrane in transfer buffer (25 mM Tris, 192 mM glycine, 0.037%
SDS, 20% methanol) by wet electroblotter at 400 mA for 120 min. The nitrocellulose
membrane was blocked overnight at 4°C with 5% non-fat milk/TBST (50 mM Tris-Cl,
pH=7.4, 150 mM NaCl, 0.1% Tween-20) or at 37°C for 1 hour. The next day, the
membrane was incubated with primary antibody (for RET51, 1:500 dilution in 5%
milk, Santa Cruz) for 2 h at room temperature. After four times washes with TBST,
the membrane was incubated with secondary antibody (1:2,000 dilution in 3% milk,
anti-goat secondary antibody, Santa Cruz) for 1 hour at room temperature on an
orbital shaker. The membrane was subsequently washed, and incubated with the
mixture of ECL detection reagents (1.5 ml solution A with 37.5 µl solution B) (Pierce,
USA) for 5 minutes in darkness. At last, the signal was detected by exposure in dark
room.
2.8 siRNA knockdown
SiRNA from Dharmacon or FirstBase were diluted to 50 µM before use. MCF7 cells
were seeded in 6 well plates in passage medium or starve medium for RNA or protein
collection. Before transfection, reaction 1 was prepared by mixing 6 µl of
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Lipofectamine RNAiMax (Invitrogen) with 44 µl of DMEM-F12, while reaction 2
was prepared by mixing 3 µl of 50 uM siRNA with 47 µl of DMEM-F12. After 10
min, the 2 reactions were mixed together and incubated for 15 min at room
temperature. Then the media in the well were removed and 1.5 ml of DMEM+5%
FBS (or DMEM-F12+5% CDFBS) without any antibiotics media was added into the
transfection tubes and then transferred into the 6-well plate. After overnight
transfection, the media in each well was changed by 2 ml fresh DMEM+5% FBS or
DMEM-F12+5% CDFBS without antibiotics. Totally after 48 hours of siRNA
transfection, the cells were harvested for either protein preps or RNA preps.
2.9 Evolutionary conservation analysis
2 nucleotide mutations to the consensus ERE sequence (GGTCAnnnTGACC)
criterion was used to find the possible ERE binding site in the 6 detect regions.
Following that, the possible ERE binding sequences were retrieved and aligned in
human (hg18), Chimp(panTro2), Rhesus(rheMac2), Mouse(mm8), Rat(rn4),
Dog(canFam2), Cow(bosTau3), Horse(equCab1), Cat(felCat3), TreeShrew(tupBel1),
Bushbaby(otoGar1) and Rabbit(oryCun1) through UCSC Genome Bioinformatics
website (http://genome.ucsc.edu/).
The bioinformatic scanning for the co-factors of ERα, such as FoxA1, AP1, AP2γ,
was identified by Genomatix and Transfec program.
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Chapter 3 Results
3.1 The RET proto-oncogene is up-regulated by estrogen
3.1.1 RET mRNA and protein expression level is upregulated by E2 stimulation
Recently, numerous groups including ours have performed extensive microarray
studies to profile genes that are regulated by estrogen in MCF7 cells. From our
analysis, we observed a moderate up-regulation of the RET gene expression by E2. In
order to investigate the RET regulation by estrogen in breast cancer in greater detail,
we first examined the time course of both isoforms of RET, RET9 and RET51, at the
mRNA and protein levels in ERα-positive MCF7 breast cancer cell lines. As shown in
Fig 1, RET9 and RET51 mRNA were significantly stimulated after 3 hours of E2
exposure, and continued to increase to a maximal around 8 fold at 6 and 12 hours
respectively. The RET51 gene was more responsive to E2 as its mRNA expression
level was amplified up to 7 fold at 3 hours post E2 treatment. In contrast, the E2
response of the RET9 gene was more gradual. RET9 expression level was only
amplified 4 folds after 3 hours, and reached its maximal exposure 6 hours later than
RET51.
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Fig 1: RET mRNA expression levels with E2 treatment in MCF7 cells. RET mRNA
expression levels were normalized with GAPDH levels and the expression level at 0
hours of EtOH samples were normalized as 1 unit. All results showed here are in
triplicates.
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At the protein level, increases in RET51 protein levels were detected as early as 3
hours post E2 treatment and continued to increase throughout the time course of
treatment (Fig 2). These observations were consistent with the earlier data on the level
of mRNA of the RET gene.
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Fig 2: RET51 protein expression level with E2 treatment in MCF7 cells. MCF7 cells
were treated with 10 nmol/l of E2 for 0 to 24 hours and total cellular lysates were
used for RET51 immunoblotting.
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3.1.2 Effect of ERα knockdown on RET mRNA expression
Since we have established that the RET gene is E2 responsive, we next examined the
requirement of ERα for E2-mediated stimulation of RET mRNA. To accomplish this,
siRNA technology was used. As shown in Fig 3, a siRNA targeted specifically to ERα
led to a 90% depletion of ERα mRNA level in MCF7 cells. MCF7 cells transfected
with ERα siRNA were stimulated with either E2 or EtOH for 8 hours and RNA
harvested. In the absence of ERα expression, RET9 RNA expression level of E2
treatment was decreased from 4.6 fold to 1.4 fold (Fig 3). Similarly, RET51 RNA
expression level decreased from 6.6 fold to 1.6 fold. The reduction in RET expression
after E2 treatment was also observed at the protein level. This abolishment of RET
up-regulation after E2 treatment suggested that the E2 up-regulation of RET is
dependent on ERα.
36
Fig 3: ERα, RET9 and RET51 mRNA expression level after ERα siRNA knockdown.
ERα, RET9 and RET51 expression levels were adjusted to GAPDH internal control.
In each group, the expression level in the control siRNA group after EtOH treatment
was normalized as 1 unit. All results showed here are in triplicates.
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3.1.3 The RET gene is a primary target of ERα
In order to confirm that RET gene is one of the primary/direct target genes of ERα,
MCF7 cells were pre-treated with the protein synthesis inhibitor cycloheximide (CHX)
prior to E2 stimulation. As shown in Fig 4, RET expression of cycloheximide and
non-cycloheximide treated cells were similar at 8 hours or 12 hours post E2 treatment.
This indicates that the RET gene is directly regulated by ERα in response to E2.
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Fig 4: RET9 and RET51 mRNA expression level with cycloheximide treatment.
MCF7 cells were pretreated with 10 ug/ml of cycloheximide (CHX) for 1 hour before
the 10 nmol/l of E2 treatment for 8 or 12 hours. RET mRNA expression levels were
adjusted to the internal control GAPDH expression level, then the expression level at
0 hours without cycloheximide treatment was normalized as 1 unit. All results showed
here are in triplicates.
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3.2 RET gene is regulated by E2 through two imperfect EREs
3.2.1 ERα binds to six ERBSs at the RET gene locus
In order to further examine the role of ERα in the regulation of RET mRNA, ChIP
assay was preformed to investigate the recruitment and binding of ERα at the RET
gene locus. Previous genome-wide ERα ChIP-Seq experiments carried out by other
members in the lab showed a cluster of six ERBSs in the region between -50 kb and
+35kb around the RET transcription start site (TSS) (Fig 5). To validate the ERBSs at
the RET gene locus, ChIP assay with anti-ERα antibody was carried out. As shown in
Fig 6, ERBS 1 and ERBS 6 showed high levels of ERα enrichment after E2 treatment
(3.6% for ERBS 1 and 1.0% for ERBS 6), respectively, whereas the other 4 ERBSs
showed low level of ERα recruitment.
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Fig 5: ERBSs of the RET gene locus. The genomic loci of RET coding region and
relevant position of the 6 ERBSs in chromosome 10 are showed here.
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Fig 6: Recruitment of ERα at six ERBSs of the RET gene locus. The qPCR results of
ERα ChIP samples were adjusted to the relative total input samples to get the
percentage input. All results showed here are in triplicates.
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3.2.2 Two of the six ERBS s are functional
To validate and further examine the function of these distal ERBSs within the RET
genomic region, 500-1000 bp region of each ERBS was amplified from the MCF7
genome and inserted into a luciferase reporter construct for transient transfection
assays. As shown in Fig 7, not all of the ERBSs were functional. Construct #1 and #6,
containing ERBS 1 and ERBS 6 respectively, were efficiently activated in an
estrogen-dependent manner similar to the positive control. The positive control is a
luciferase reporter construct containing 2 consensus EREs cloned upstream of a
TATA box (pGL4-2ERE-TATA). In response to E2, the relative luciferase activity of
ERBS 1 and ERBS 6 were 8 and 10 folds higher than EtOH, respectively. The results
indicated that these two ERBSs have ERα recruitment ability and function as
enhancers to activate transcription of the RET gene after E2 stimulation.
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Fig 7: Functional analysis of the six ERBS through transient transfection. The basic
structures of the plasmids are showing below. The luciferase expression level detected
by the reporter system was normalized to the co-transfected Renilla level in order to
get the Relative Luciferase Unit (RLU). All results showed here are in triplicates.
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3.2.3 Mutagenesis confirmed the function of EREs in these two ERBSs
Sequence analysis of these six putative ERBSs revealed that there are three imperfect
EREs within ERBS 1, ERBS 2 and ERBS 6, respectively. According to the
functionality of these ERBS, we focused on ERE I and ERE III to validate the
function of these imperfect EREs. Compared to the consensus ERE motif,
GGTCANNNTGACC, both ERE I (CCTCAgggTGACC) and ERE III
(GGTTGcctTGACC) contain two mismatches (Fig 8). Mutations were introduced into
these two ERBSs using site-directed mutagenesis. ERE I was mutated to
CCAGAgggTGATT, while ERE III was mutated to AATTGcctTGATA. As shown in
Fig 8, transfection results showed that mutations to the imperfect ERE I of ERBS 1
and ERE III of ERBS 6 almost completely abrogated their transcriptional activity.
The results indicated that these two ERBSs are bona fide ERα transcriptional
enhancers.
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Fig 8: Mutation analysis of ERBS 1 and ERBS 6 through transfection. The consensus
ERE motif, EREs containing in these two ERBSs and the mutations introduced were
indicated below. Luciferase expression was adjusted to the co-transfected renilla level
to generate RLU. PC and NC stand for Positive Control and Negative Control,
respectively. All results showed here are in triplicates.
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3.3 Two ERBSs interact with the transcription start site
3.3.1 3C assay detected three E2 dependent long range chromatin interactions around
the RET
The recruitment of ERα to the distal enhancers upstream and downstream of the RET
gene suggested that the E2 mediated stimulation of RET may occur via long range
chromatin interaction. To test this, we preformed chromosome conformation capture
(3C) assays to examine the putative interactions of the -50 kb and +35 kb enhancers
with the TSS.
Firstly, a series of primers were designed unidirectionally at restriction enzyme
digestion sites for each of the 6 ERBSs (Fig 9). An additional primer designed further
downstream of the RET coding sequence was used as negative control. The unique
primers were combined with one another in the quantitative PCR process to detect the
interaction frenquency between each paired regions. For example, the data presented
by primer B with primer D reflected the interaction frequency between ERBS 1 and
ERBS 2. All primers used in the experiments and their relative positions are shown in
Fig 9.
Using primer B as our anchor point, we measured the relative interaction frequency of
restriction enzyme digested fragments containing ERBS across the RET locus. As
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shown in Fig 10, strong interactions were detected between ERBS 1 and ERBS 6 as
expected. Since ERBS 2, 3 and 4 had minimal transcriptional ability, interactions of
ERBS 1 with ERBS 2, ERBS 3 and ERBS 4 were low. However, a relatively high
interaction frequency was detected between ERBS 1 and ERBS 5, although ERBS 5
did not contain a ERE motif nor had functional activity.
As expected interaction frequency between the anchor point (primer B) and its
surrounding regions (primers A,C,D,E) were high due to random molecular collision
and they represented positive control interactions of this assay. As the distance from
the anchor point increased, interaction frequency due to random molecular collision
decreased. Furthermore, these four interactions were E2 independent. In contrast, two
interactions between ERBS 1 with ERBS 5 and ERBS 6 (represented by primer sets
B-I, B-J) showed strong E2 dependence.
Since ERBS 5 and ERBS 6 both interact with ERBS 1, we investigated whether these
two ERBSs also interact with each other. The results showed in Fig 10 indicated that
the interactions frequency between ERBS 5 and 6 were as strong as the ones between
ERBS 1 and 5, or between ERBS 1 and 6. This interaction was also highly E2
dependent.
48
Fig 9: Overview of ERBS location and primers designed for 3C assay. The blue
breaks indicate the Xho II enzyme digestion sites in this region. Primer B, F, G, H, I
and J represent the 6 ERBSs respectively, while primer A, C, D, E and K are primers
designed as controls.
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Fig 10: Long range chromatin interaction at the RET gene locus through 3C. The X
axis indicates the primer sets used to detect the possible interactions. The qPCR
results of each primer set in the 3C chromatin samples were normalized to the results
of each primer set in the BAC samples first, to account for the primer efficiency
differences. Then the results of EtOH or E2 stimulated samples were further
normalized to the results of an independent locus, which exists in an E2 unaffected
region in chromosome 15, to get the percentage of interaction frequency. The DNA
fragments amplified were sequenced and mapped back into the Human Genome
Browser (UCSC). All results showed here are in triplicates.
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3.3.2 Long range chromatin interactions at the RET gene requires ERα
Even though ERBS 5 has neither a ERE motif nor transcriptional enhancer activity, its
position is nearest to the promoter region. This suggests that E2 dependent RET gene
expression may be regulated through functional interaction between the enhancers
(ERBS 1 and ERBS 6) with the promoter region (ERBS 5) of the RET gene. All three
combinations of these ERBS showed a 2~3 fold interaction frequency that were also
E2 dependent.
In order to confirm the role of ERα in the mediation of these long range chromatin
interactions, the 3C assay were carried out in MCF7 cells transfected with or without
siRNA targeted to ERα. After successful knockdown of ERα, as shown in Fig 11, the
3C assay results showed a general decrease in all three main interactions, compared to
the control siRNA. The interaction frequency in the EtOH samples was decreased to
1/3 to 1/4 of the control siRNA samples. E2 responses were also lost. In contrast, the
positive control interactions, mediated by random molecular interactions, were not
affected.
Through the 3C assay, we have demonstrated E2 dependent interaction of the distal
enhancers with the proximal promoter of the RET gene, in vivo. Taken together, these
3C data suggested that the ERα regulated enhancers transactivate the RET gene via an
intrachromosomal looping mechanism.
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Fig 11: Long range chromatin interaction at the RET gene locus after ERα siRNA
knockdown. Anti-ERα siRNA or control siRNA was first transfected in starved
MCF7 cells 48 hours prior to the 3C assay. The western blotting results above show
the successful deprivation of ERα. The data generated here were the same as normal
3C assay. All results showed here are in triplicates.
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3.4 Role of other co-factors in long range chromatin interactions
around RET
3.4.1 Binding of other co-factors at the RET locus through ChIP
Using bioinformatic tools such as Genomatix and Transfac to detect for the
enrichment of binding motifs of other transcription factors at the ERBS, we showed
that some of the enriched motifs are bound by co-factors which have been previously
reported to be co-regulators of ERα. These co-factors include FoxA1 (Robyr,
Gegonne et al. 2000) and cJun (Umayahara, Kawamori et al. 1994) (Fig 12).
In order to validate the recruitment of these co-factors around the ERBSs, ChIP
experiments were carried out for each of the factors. As shown in Fig 13, cJun was
recruited mainly at ERBS 1, at 0.02% of input and 0.07% of input before and after E2
treatment respectively. FoxA1 was recruited at ERBS 1, 3 and 5.
Based on the ERα co-localization transcription factor list generated from other
members of the lab, we also detected the binding of some novel factors within the
ERBSs around RET gene locus. Among them, AP2γ was detected at all the 6 ERBSs.
AP2γ binding was strongest at ERBS 1, 3 and 5 with enrichment at 0.14-0.18% of
input (Fig 14).
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Fig 12: Prediction of other co-factor at ERBS 1 and ERBS 6 through motif analysis.
The relative positions of these co-factor motifs are showed here.
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Fig 13: cJun and FoxA1 binding at the RET locus. Primers used here were the same
as those in detecting ERα recruitment in these 6 ERBSs. All results showed here are
in triplicates.
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Fig 14: AP2γ binding at the RET locus. Primers used here were the same as those in
detecting ERα recruitment in these 6 ERBSs. All results showed here are in
triplicates.
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3.4.2 Mutagenesis of the co-factor motif decreased ERα enhancer ability
To confirm the activity of the above co-factors in assisting ERα at the ERBSs,
specific point mutations were introduced to reporter constructs containing ERBS 1 or
6. As shown in Fig 15, there was a decrease in E2 response when the binding motifs
were mutated. At ERBS 1, mutations at AP1, AP2γ, and FoxA1 motif resulted in a
50% decrease in transcriptional activity. At ERBS 6, mutations of these 3 co-factors
caused 50-75% decrease in transcriptional activity. The results suggest that these
ERBSs were functional in the recruitment of relevant transcription factors to enhance
E2 dependent transcription.
57
Fig 15: Mutation analysis of ERBS with co-factor motif. The motif of the co-factor
was labeled behind the binding region number. The RLU value was calculated in the
same way as previous described. All results showed here are in triplicates.
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3.4.3 AP2γ is required for RET gene expression
To further explore the function of the novel transcription factor, AP2γ, we used
siRNAs to knockdown this transcription factor and measured its effect on RET gene
expression. As shown in Fig 16, knockdown of AP2γ decreased RET expression by
30% at the mRNA level. Similar results were detected at the protein level.
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Fig 16: Protein and mRNA expression of RET after AP2γ siRNA knockdown.
Anti-RET51 antibody was used to detect RET51 protein level. RNA was collected
after 8 hours of E2 or EtOH stimulation post 48 hours of relative siRNA transfection.
RET9 and RET51 cDNA primers used were the same as used previously.
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3.4.4 Recruitment of ERα to the estrogen receptor binding sites of RET is dependent
on AP2γ
Since AP2γ was recruited to the ERBS of the RET gene locus and knockdown of
AP2γ resulted in a decrease of RET transcriptional level, we next investigated
whether AP2γ can affect the recruitment of ERα to these ERBSs.
In this experiment, MCF7 cells were transfected with AP2γ siRNA or control siRNA
for 48 hours followed by ChIP with an ERα specific antibody. As shown in Fig 17,
knockdown of AP2γ affected recruitment of ERα at all the 6 ERBSs. At ERBS 1, the
recruitment of ERα after E2 treatment decreased from 3.8% to 1.3%, while at ERBS 6,
the recruitment of ERα decreased from 0.7% to 0.2%. These results strongly suggest
that AP2γ plays a functional role in mediating ERα recruitment at these 6 ERBSs.
61
Fig 17: ERα binding at the RET locus after AP2γ knockdown. MCF7 cells were
processed to ChIP assay after 48 hours of transfection of AP2γ siRNA or control
siRNA. ChIP primers of these 6 ERBSs were the same as previously used. All results
showed here are in triplicates.
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3.4.5 AP2γ affects ERα mediated long range interactions
The importance of AP2γ in ERα recruitment to these 6 ERBSs suggested that AP2γ
may also affect the chromatin loop mediated by ERα at the RET gene locus. To test
this, 3C assay after AP2γ knockdown was performed in the same way as previously
described for ERα knockdown 3C assay. The results in Fig 18 showed that AP2γ
knockdown affected the 3 key long range chromatin interactions at the RET locus.
Even though the basal interaction frequency of EtOH treated samples remained the
same, the 2-3 fold increase in interaction frequency after E2 stimulation was lost in
AP2γ knockdown samples. This indicated that the E2 dependent chromatin loop
mediated by ERα was abolished. The results are consistent with the decrease in RET
gene expression after AP2γ knockdown (Fig 16).
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Fig 18: Long range chromatin interaction at the RET gene locus after AP2γ siRNA
knockdown. MCF7 cells were transfected by AP2γ or control siRNA for 48 hours
then proceeded to 3C assay. The primer sets were the same as previously used.
Results showed here are in triplicates.
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3.5 Conservation of the RET gene’s ERα binding sites
Since RET gene is evolutionary conserved in the mammalian genome, we compared
the RET locus of different species whose genomes have been sequenced, and found
that the EREs around the RET locus are also evolutionarily conserved. As shown in
Table 6, the conservation of ERE shows a parallel pattern, and they are most
conserved in mammalian genomes.
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ERE I (in ERBS1) ERE II (in ERBS 2) ERE III (in ERBS 3)
Human(hg18) CCTCAGG-GTGACC GGTCACAATAACC GGTTGCCTTGACC
Chimp(panTro2) CCTCGGG-GTGACC GGTCACAATAACC GGTTGCCTTGACC
Rhesus(rheMac2) CCTCAGG-GTGACC N GGTTGCTTTGACC
Mouse(mm8) N GGAGGAAGTAATA N
Rat(rn4) N AGAGGAAATAATA N
Dog(canFam2) CTGCAGGGGTGACC GGGCAACATAATA TGTC-CTTTCACC
Cow(bosTau3) N GGGCAAAATAATA TGTTCTTTCCACC
Horse(equCab1) CCACAGGCTGGACC GGGCAAAACAATA AGTTGCTTTCACC
Cat(felCat3) N GGGCAAAATAATA AGTT-CTTCCACC
TreeShrew(tupBel1) N GGGCAC-ATAACA N
Bushbaby(otoGar1) N GGGCAAAATAATA N
Rabbit(oryCun1) N N N
Table 6: Revolutionary conservation analysis of three ERE sites around RET gene.




4.1 RET is E2 regulated through ERα mediated long range
interaction
From our ERα ChIP assay, we found 6 ERBSs associated with the RET region.
Among them, two (ERBS 1 and ERBS 6) showed high level of binding affinity while
the rest showed relatively low binding affinity (Fig 6). Subsequent reporter assays
confirmed that these two ERBSs were ERα specific while the remaining four were not
(Fig 7). In addition, the 3C assay results confirmed the presence of ERα mediated
long range interaction between ERα enhancers, 50kb upstream and 33kb downstream
of the RET gene promoter region is E2 dependent (Fig 11). In this model, the ERBS 5,
which represents the promoter region, acts as an anchor for the two enhancers to
initiate RNA Pol II gene transcription through ERα activation. Here, we provide
evidence that distal ERBS, up to 50kb away, is a bona fide transcriptional enhancer
that is critical for maximal transcription activity. At the same time, an ERα enhancer
further downstream in the RET gene coding region, was also functional in the
transcriptional activation of RET gene. Further bioinformatic analysis showed that
other co-activators such as AP2γ collaborate with ERα and RNA Pol II complex to
consolidate and initiate active transcription (Fig 14, 16). The two imperfect EREs in
each of the enhancers play a major role in the determination of the overall
transcriptional activity of the promoter (Fig 8). Comparison made across different
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species indicates there is a high level of evolutionarily conservation of these EREs
(Table 6). Taken together, these two imperfect ERE recruited ERα to bind after E2
stimulation and loop towards the promoter area to recruit RNA Pol II and other
factors to form a functional transcription complex which activates the RET gene
expression.
The interactions between the two ERBSs and the promoter region of RET gene were
also detected after E2 stimuli in the CHIA-PET assay (Fig 19). However, there are
also interaction PETs between the other four ERBSs which was not detected by the
3C assay. This difference could be due to the low efficiency of enzyme digesting,
ligation and PCR amplification during 3C assay, which makes 3C assay suitable
mainly in the detection of high frequency interactions. The detection of low frequency
interactions by the ChIA-PET assay has demonstrated that intrachromosomal looping
around RET gene locus is far more complex than anticipated.
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Fig 19: Overview of ChIA-PET interaction around the RET gene locus. Each line
indicates a pair of PETs connecting the 2 different genomic locations.
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4.2 RET gene plays a functional role in human breast cancers
RET is one of the driving oncogenes first identified in various neoplasms of the
thyroid. Further research indicated that this gene is also functional in other kinds of
tumors (Okada, Takeyama et al. 1999; Thomas, Baker et al. 2007; Boulay, Breuleux
et al. 2008; Zeng, Cheng et al. 2008). RET, as a member of the transmembrane
protein kinases, has been show to be connected to various pathways which leads cell
to proliferation and survival (Manie, Santoro et al. 2001; Paratcha, Ledda et al. 2001).
In ERα positive breast cancer cell line MCF7, it has been demonstrated that RET was
activated by the ligand GDNF (glial-derived neurotrophic factor) which leads to the
initiation of downstream signaling proteins such as ERK and AKT of the PI3K
pathway (Esseghir, Todd et al. 2007). While earlier work has reported the role of the
PI3K pathway in the phosphorylation of ERα, our work suggest a possible additional
connection between the pathways. In RET siRNA knockdown samples, we found that
ERα regulated genes, such as GREB1, displayed a different expression pattern after
E2 stimulation. Building on previous work and ours, we proposed a feedback kinase
dependent intrachromosomal interaction that may be dependent on ERα and RET.
In this model, ERα is activated after E2 stimulation and induces the transcription of its
target genes. With the subsequent upregulation of RET gene expression, ERα is
phosphorylated by other kinases downstream of the RET signaling pathway.
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Phosphorylation of ERα maintains its transcriptional activity. Further studies will be
needed to test this postulated cross talk between the regulated pathways of ERα and
RET.
4.3 AP2γ functions as a pioneer factor for ERα response pathway
Previous studies have shown that certain transcription factors, such as FoxA1, cJun
and cFos, assist ERα in the regulation of downstream targets gene in pathways related
to breast cancer. In this work, the role of a novel ERα co-factor, AP2γ, in E2
dependent regulation of RET was investigated (Fig 14, 16). AP2γ belongs to the
family of activating enhancer-binding protein 2 (AP-2) transcription factors, whose 5
members share a high homology (Eckert, Buhl et al. 2005). All five members have
similar multidomain structures which consist of a proline-rich transactivation domain,
a highly conserved basic helical DNA-binding domain, and a dimerization domain
that perimits homodimerization or heterodimerization.
Previous works have established a link between AP2γ and breast cancer in the direct
regulation of ERα gene expression and in cell proliferation and differentiation (Turner,
Zhang et al. 1998; Woodfield, Horan et al. 2007; Orso, Penna et al. 2008). Here, we
identified an additional function of AP2γ as a co-regulator of ERα (Fig 14, 15, 16).
While binding of AP2γ was specific at the RET gene locus, the recruitment of AP2γ
was E2 independent (Fig 14). This suggests that AP2γ is already recruited to the
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target regions before E2 stimulation. Loss of ERα recruitment after AP2γ siRNA
knockdown indicated that the presence of AP2γ was a necessary requirement for ERα
recruitment at the RET locus (Fig 17). Consequently, the loss of ERα recruitment
abrogated intrachromosomal interaction at the region (Fig 18).
Although previous research indicated that AP2γ regulates ERα transcription
(Woodfield, Horan et al. 2007), our AP2γ siRNA knockdown samples did not show
obvious changes of ERα at both mRNA and protein levels. Furthermore, target genes
of ERα, such as GREB1 and TFF1, did not show obvious expression changes after
AP2γ siRNA knockdown (data not shown). In addition, the ERα recruitments at the
enhancer and promoter region of GREB1 gene were not obviously affected (data not
shown). These results suggested that AP2γ alone was not able to change the
regulation network conducted by ERα. The RET gene provides an example of an
AP2γ dependent ERα regulated gene, which E2 regulation is mediated through long
range chromatin interaction. The recruitment of ERα and the transactivation process is
mediated by a transcriptional complex consisting of ERα and other co-factors,
indicating AP2γ maybe primarily involved in long range chromatin interaction. The
preloading of AP2γ onto the ERBSs may function mainly as the anchors for the
looping process. The exact function of AP2γ in ERα mediated transactivation process
requires further research works to fully elucidate.
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Chapter 5 Conclusion
Our research demonstrated that ERα conducted long range chromatin loops were
mainly responsible for the transcriptional regulation of RET gene in breast cancer cell
line MCF7 after E2 treatment. This chromatin loops connected two ERα binding sites
which separated 85 kb away from each other and conducted the complex to the
promoter region to recruit RNA Pol II to start transcription. During this process, the
function of ERα was carried out with the assistance of some other co-factors, such as
AP2γ, cJun, FoxA1, etc. Of them, AP2γ is discovered to be the pre-loading factor for
ERα and is important for the formation of the transactivation looping. The
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